A Phase I Study of BGB-11417 in People with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma

Share
Print

Full Title

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Purpose

BGB-11417 is an investigational drug that may be an effective treatment for B-cell cancers because it works in almost the same way as an approved drug called venetoclax, which has been shown to be an effective treatment for some B-cell lymphomas. BGB-11417 selectively blocks a protein in these cancers, which may slow or stop the growth of cancer cells at lower doses and more effectively than venetoclax. In this study, researchers are finding the highest dose of BGB-11417 that can be given safely in patients with B-cell non-Hodgkin lymphoma that has come back or continued to grow despite prior treatment. BGB-11417 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have B-cell non-Hodgkin lymphoma that came back or continued to grow despite prior treatment.
  • Patients should recover from the serious side effects of previous therapies before receiving BGB-11417.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Erel Joffe at 646-608-3703.

Protocol

21-187

Phase

I

Investigator

Co-Investigators